Medistep Health.

How has been the historical performance of Medistep Health.?

Medistep Health has shown significant growth over the past three years, with net sales increasing from 7.46 Cr in Mar'23 to 49.65 Cr in Mar'25, and profit after tax rising from 0.41 Cr to 4.14 Cr. The company has also improved its equity capital and cash flow management during this period.

Answer:<BR>The historical performance of Medistep Health shows significant growth over the past three years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Medistep Health's net sales increased from 7.46 Cr in Mar'23 to 31.62 Cr in Mar'24, and further to 49.65 Cr in Mar'25, indicating a strong upward trend. Total operating income mirrored this growth, rising from 7.46 Cr in Mar'23 to 49.65 Cr in Mar'25. The total expenditure also rose significantly from 6.87 Cr in Mar'23 to 44.06 Cr in Mar'25, reflecting the company's expansion efforts. Operating profit (PBDIT) improved from 0.59 Cr in Mar'23 to 5.59 Cr in Mar'25, while profit before tax rose from 0.55 Cr to 5.54 Cr in the same period. Profit after tax followed suit, increasing from 0.41 Cr in Mar'23 to 4.14 Cr in Mar'25. The company's equity capital grew from 1.07 Cr in Mar'23 to 10.47 Cr in Mar'25, and total liabilities increased from 14.95 Cr to 22.98 Cr. Cash flow from financing activities showed a net inflow of 1.00 Cr in Mar'25, compared to an outflow of 7.00 Cr in Mar'24, indicating improved cash management. Overall, Medistep Health has demonstrated robust growth in sales and profitability, alongside an increase in equity and total assets.

Is Medistep Health. overvalued or undervalued?

As of November 13, 2025, Medistep Health is considered very attractive with a PE ratio of 9.37 and an EV to EBIT ratio of 6.86, significantly lower than its peers, indicating it is undervalued despite a strong recent weekly return of 21.88%.

As of 13 November 2025, the valuation grade for Medistep Health. has moved from does not qualify to very attractive. This indicates a significant improvement in its valuation outlook. The company is currently assessed as undervalued, supported by a PE ratio of 9.37, an EV to EBIT ratio of 6.86, and a robust ROCE of 34.41%. <BR><BR>In comparison to its peers, Medistep Health. stands out with a much lower PE ratio than Sun Pharma (36.15) and Divi's Lab (70.4), both of which are categorized as expensive. Additionally, its EV to EBITDA ratio of 6.82 is significantly more favorable than the industry averages, reinforcing its attractive valuation. While Medistep Health. has shown a strong weekly return of 21.88% compared to the Sensex's 1.45%, its longer-term performance metrics remain to be seen.

Which are the latest news on Medistep Health.?

Why is Medistep Healthcare Ltd falling/rising?

As of 12-Feb, Medistep Healthcare Ltd's stock price is at 23.70, down 1.46%, and has underperformed its sector. Declining investor participation and erratic trading patterns are contributing to its current bearish trend.

As of 12-Feb, Medistep Healthcare Ltd's stock price is currently at 23.70, reflecting a decrease of 0.35, or 1.46%. The stock has underperformed its sector by 1.26% today, indicating a weaker performance compared to its peers. Additionally, the stock has shown erratic trading patterns, having not traded on one day out of the last 20 days. <BR><BR>Investor participation appears to be declining, as evidenced by a delivery volume of 6,000 shares on February 10, which represents a 33.33% drop compared to the 5-day average delivery volume. This decline in trading activity may contribute to the stock's downward pressure. <BR><BR>While the stock has performed positively over the past week with a gain of 3.95%, it has seen a significant decline of 12.06% over the past month. Furthermore, the stock is currently trading higher than its 5-day and 20-day moving averages but lower than its 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend in the longer term. <BR><BR>Overall, the combination of declining investor participation, underperformance relative to the sector, and recent erratic trading behavior are contributing factors to the stock's current decline.